Table 1.

Patient demographics, n = 193

Characteristic	No. (%)
Age, median (IQR)	64 (56–70)
Sex: Male	103 (53.3%)
Race: White	145 (75.1%)
ECOG, median (IQR)	1 (1–2)
Cancer type
Melanoma	1 (0.5%)
Genitourinary cancer	3 (1.6%)
Gastrointestinal cancer	2 (1.0%)
Hematologic cancer	187 (96.9%)
PI used for cancer treatment
Bortezomib	114 (59.1%)
Carfilzomib	55 (28.5%)
Ixazomib	24 (12.4%)
All-cause mortality	90 (46.6%)
Follow-up duration, years	1.3 (0.4–3.3)

ECOG, Eastern Cooperative Oncology Group performance status; IQR, interquartile range